EAGLE PHARMACEUTICALS INC (EGRX) Stock Price, Quote, News and Overview
NASDAQ:EGRX - Nasdaq - US2697961082 - Common Stock - Currency: USD
EGRX Quote, Performance and Key Statistics
2.14
-1.42 (-39.89%)
The current stock price of EGRX is 2.14 USD. In the past month the price decreased by -53.58%. In the past year, price decreased by -84.56%.
EGRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About EGRX
Company Profile
Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana. The Company’s subsidiaries include Eagle Biologics, Inc., Eagle Research Lab Limited, Acacia Pharma Group plc, Acacia Pharma Limited and Acacia Pharma Inc.
Company Info
EAGLE PHARMACEUTICALS INC
50 Tice Boulevard, Suite 315
Woodcliff Lake NEW JERSEY 07677 US
CEO: Scott Tarriff
Employees: 134
Company Website: https://www.eagleus.com/
Phone: 12013265300
EAGLE PHARMACEUTICALS INC / EGRX FAQ
What is the stock price of EAGLE PHARMACEUTICALS INC today?
The current stock price of EGRX is 2.14 USD. The price decreased by -39.89% in the last trading session.
What is the ticker symbol for EAGLE PHARMACEUTICALS INC stock?
The exchange symbol of EAGLE PHARMACEUTICALS INC is EGRX and it is listed on the Nasdaq exchange.
On which exchange is EGRX stock listed?
EGRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EAGLE PHARMACEUTICALS INC stock?
7 analysts have analysed EGRX and the average price target is 17.34 USD. This implies a price increase of 710.28% is expected in the next year compared to the current price of 2.14. Check the EAGLE PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EAGLE PHARMACEUTICALS INC worth?
EAGLE PHARMACEUTICALS INC (EGRX) has a market capitalization of 27.80M USD. This makes EGRX a Nano Cap stock.
How many employees does EAGLE PHARMACEUTICALS INC have?
EAGLE PHARMACEUTICALS INC (EGRX) currently has 134 employees.
What are the support and resistance levels for EAGLE PHARMACEUTICALS INC (EGRX) stock?
EAGLE PHARMACEUTICALS INC (EGRX) has a resistance level at 5.24. Check the full technical report for a detailed analysis of EGRX support and resistance levels.
Is EAGLE PHARMACEUTICALS INC (EGRX) expected to grow?
The Revenue of EAGLE PHARMACEUTICALS INC (EGRX) is expected to decline by -19.31% in the next year. Check the estimates tab for more information on the EGRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EAGLE PHARMACEUTICALS INC (EGRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EGRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EGRX, evaluating the profitability, health, valuation and growth aspects
- EAGLE PHARMACEUTICALS INC (EGRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EAGLE PHARMACEUTICALS INC (EGRX) Sales and EPS estimates to see what analysts future expectations are.
- EAGLE PHARMACEUTICALS INC (EGRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EAGLE PHARMACEUTICALS INC (EGRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- EAGLE PHARMACEUTICALS INC (EGRX) Stock Chart to make your own analysis
- EAGLE PHARMACEUTICALS INC (EGRX) Latest news and press-releases to stay up to date.
Does EAGLE PHARMACEUTICALS INC (EGRX) stock pay dividends?
EGRX does not pay a dividend.
When does EAGLE PHARMACEUTICALS INC (EGRX) report earnings?
EAGLE PHARMACEUTICALS INC (EGRX) will report earnings on 2024-11-04, after the market close.
What is the Price/Earnings (PE) ratio of EAGLE PHARMACEUTICALS INC (EGRX)?
The PE ratio for EAGLE PHARMACEUTICALS INC (EGRX) is 0.46. This is based on the reported non-GAAP earnings per share of 4.66 and the current share price of 2.14 USD. Check the full fundamental report for a full analysis of the valuation metrics for EGRX.
What is the Short Interest ratio of EAGLE PHARMACEUTICALS INC (EGRX) stock?
The outstanding short interest for EAGLE PHARMACEUTICALS INC (EGRX) is 1% of its float. Check the ownership tab for more information on the EGRX short interest.
EGRX Technical Analysis
EGRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EGRX. EGRX has an excellent profitability rating, but there are concerns on its financial health.
EGRX Financial Highlights
Over the last trailing twelve months EGRX reported a non-GAAP Earnings per Share(EPS) of 4.66. The EPS decreased by -33.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.7% | ||
| ROA | 2.99% | ||
| ROE | 4.8% | ||
| Debt/Equity | 0.25 |
EGRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to EGRX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -40.26% and a revenue growth -19.31% for EGRX